Analysts speculate that more buyouts may be in Covidien's near future; Regulatory and economic uncertainties drive a slowdown in hospital capital spending; Medic Vision and BRIT Systems sign U.S. deal for SafeCT; ConvaTec buys AbViser Medical for an undisclosed amount; Corpak acquires Micronix's assets; Synexus nabs Osteomed, terms not disclosed; HCL Technologies and Becton Dickinson join R&D forces; EndoEvolution licenses its MIS suturing device to Edwards Lifesciences'; Teleflex hits a new 52-week high; plus, a Funding Roundup and analysts' ups and downs.
The Mansfield, Mass.-based company may be looking to pick up some assets in hypertension treatment, or may keep its sights on additional acquisitions in Israel.
A report by MedCity News speculated that Covidien's support for Maya Medical's renal denervation systems may soon lead to a buyout.
An unnamed investor told Israel's Globes business news that Covidien will likely be on the lookout for "activities in their existing areas or areas in which their major competitors are not operating."
That may include pulmonary devices, anesthetics intensive care and monitoring, the investor added.
Covidien picked up 3 Israeli device makers on its recent shopping spree. The company spent spent $300 million for patient monitoring device maker Oridion (SWF:ORIDN), $300 million plus possible earnouts for superDimension and an undisclosed amount for hernia mesh maker PolyTouch Medical Ltd.
Covidien this week also closed the $108 million acquisition of Newport Medical Instruments, a deal initially announced in March.
The FDA plans a public workshop on robotically-assisted surgical devices to solicit feedback on how...
Regdy blog's Andrew Ahn discusses the advantages of getting your device approved by FDA.
EndoChoice says it raised $57 million from a syndicate of prior and new backers it plans to use boost...
Europe's top court rules that Boston Scientific must cover the cost of replacing defective pacemakers...
Medtronic invests in anti-leg-cramp drug maker Flex Pharma's initial public offering.